<div id="readability-page-1">07:24 AM EST, 01/02/2026 (MT Newswires) -- XORTX Therapeutics ( XRTX ) said Friday that peer-reviewed independent research lend further support to the company's approach to treating gout, kidney and other diseases by inhibiting xanthine oxidase (XO).XORTX's planned clinical trial using its commercial formulation of oxypurinol will bring it closer to preparing a new drug application for this gout therapy, a statement said.&#34;These discoveries highlight an opportunity to develop a personalized therapeutic approach for individuals whose unique genetic factors predispose them to disease, and the need for xanthine oxidase inhibition to treat those individuals at risk,&#34; said chief executive Allen Davidoff.The company also provided an update on its acquisition of the renal anti-fibrotic therapeutic program from Vectus Biosystems, an Australian Securities Exchange-listed company, first announced last October. Closing is expected by Jan. 13, and Vectus is waiting to hear from the ASX on whether shareholder approval is required for the sale of the VB4-P5 intellectual property. Both companies remain committed to finalizing the acquisition, a statement said.Xortx has also reduced its board to five members after three members resigned and the appointment of Krysta Davies Foss as a director. Foss is chief executive officer of Triad Strategic Services, a pharma and biotech strategy consulting firm. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

XRTX

XORTX Therapeutics 宣佈，經過同行評審的研究支持其通過抑制黃嘌呤氧化酶的痛風治療方法。該公司計劃為其氧嘌呤醇製劑進行臨牀試驗，朝着新藥申請邁進。首席執行官 Allen Davidoff 強調了基於遺傳易感性的個性化治療的潛力。此外，XORTX 正在完成從 Vectus Biosystems 收購腎臟抗纖維化項目的交易，預計將在 1 月 13 日之前完成。由於近期的辭職，董事會成員已減少至五人，Krysta Davies Foss 被任命為新董事

XORTX Therapeutics 表示，已發表的研究支持該公司在痛風治療上的方法